NEW YORK — In a fine-tuning of its executive leadership, Pfizer Inc. has named Albert Bourla as chief operating officer, a newly created position. Pfizer said Bourla, 56, currently group president of the Pfizer Innovative Health business unit, is slated to start in the COO role on Jan. 1. With the move, chairman and chief
NEW YORK — Pfizer Inc. is assessing strategic options for its Pfizer Consumer Healthcare subsidiary, including a potential sale. The pharmaceutical giant said this week that it’s considering “a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction.” However, the company noted that it may decided
NEW YORK — Pfizer says that it’s not going to split up. The pharmaceutical giant announced Monday that, following an extensive evaluation, its board of directors and executive leadership team decided to keep the company’s current structure and not pursue a separation of Pfizer Innovative Health and Pfizer Essential Health into their own publicly traded
NEW YORK — Boosting its oncology portfolio, Pfizer Inc. plans to acquire biopharmaceutical company Medivation for $14 billion in cash. Under the deal announced Monday, Pfizer is paying $81.50 a share in cash for San Francisco-based Medivation, whose products include XTANDI (enzalutamide), an androgen receptor inhibitor that the companies said is the nation’s leading novel
